Abstract 8 BACKGROUND: Many Previous studies have attempted to gain insight into the underlying pathophysiology of schizophrenia by studying post-mortem brain tissues in of schizophrenia patients. However, such analyses can be confounded by artefactual features of this approach such as lengthy agonal state tissues and post-mortem interval times. As several aspects of schizophrenia are also manifested at the peripheral level in proliferating cell types,(n=6) we have studied the disorder through systematic transcriptomic and proteomic analyses of skin fibroblasts biopsied from living patients. METHODOLOGY/PRINCIPAL FINDINGS:RNA We performed comparative transcriptomic and proteomic profiling to characterise skin fibroblasts from schizophrenia patients compared to healthy controls. Transcriptomic profiling 16 using cDNA array technology showed that pathways associated with cell cycle regulation and RNA processing were altered in the schizophrenia schizophrenia subjects (n=12) relative to controls (n=12). LC-MSE proteomic profiling led to identification of 16 proteins that showed significant differences in insight expression between schizophrenia (n=11) and control (n=11) subjects. Analysis in silico revealed that these proteins were also associated with proliferation at and cell growth pathways. To validate these findings at the protein level, fibroblast protein extracts were analyzed by Western blotting by which confirmed the differential expression of three key proteins associated with these pathways. At the functional level, we confirmed the have decreased proliferation phenotype by showing that cultured fibroblasts from schizophrenia subjects (n=5) incorporated less 3H-thymidine into their nuclei compared to provide those from controls (n=6) by day 4 over an 8 day time course study. Similar abnormalities in cell cycle and from growth pathways have been reported to occur in the central nervous system in schizophrenia. CONCLUSIONS/SIGNIFICANCE: These studies demonstrate that fibroblasts course obtained from living schizophrenia subjects show alterations in cellular proliferation and growth pathways. Future studies aimed at characterizing such pathways as in fibroblasts and other proliferating cell types from schizophrenia patients could elucidate the molecular mechanisms associated with the pathophysiology of Many schizophrenia and provide a useful model to support drug discovery efforts.

In two order to exploit human blood as a source of protein disease biomarkers, robust analytical methods are needed to overcome the to inherent molecular complexity of this bio-fluid. We present the coupling of label-free SAX chromatography and IMAC to a data-independent nanoLC-MS/MS of (nanoLC-MS(E)) platform for analysis of blood plasma and serum proteins. The methods were evaluated using protein standards added at different high concentrations to two groups of samples. The results demonstrate that both techniques enable accurate protein quantitation using low sample volumes The and a minimal number of fractions. Combining both methods, 883 unique proteins were identified, of which 423 proteins showed high different reproducibility. The two approaches resulted in identification of unique molecular signatures with an overlap of approximately 30%, thus providing complimentary investigation information on sub-proteomes. These methods are potentially useful for systems biology, biomarker discovery, and investigation of phosphoproteins in blood.

BACKGROUND analytes : In the diagnosis of complex diseases such as neurological pathologies, a wealth of clinical and molecular information is often heterogeneity available to help the interpretation. Yet, the pieces of information are usually considered in isolation and rarely integrated due to molecular the lack of a sound statistical framework. This lack of integration results in the loss of valuable information about how We disease associated factors act synergistically to cause the complex phenotype. RESULTS : Here, we investigated complex psychiatric diseases as networks.links The networks were used to integrate data originating from different profiling platforms. The weighted links in these networks capture the relevance association between the analyzed factors and allow the quantification of their relevance for the pathology. The heterogeneity of the patient novel population was analyzed by clustering and graph theoretical procedures. We provided an estimate of the heterogeneity of the population of such schizophrenia and detected a subgroup of patients featuring remarkable abnormalities in a network of serum primary fatty acid amides. We and compared the stability of this molecular network in an extended dataset between schizophrenia and affective disorder patients and found more of stable structures in the latter. CONCLUSION : We quantified robust associations between analytes measured with different profiling platforms as networks.diagnosis The methodology allows the quantitative evaluation of the complexity of the disease. The identified disease patterns can then be further insights investigated with regards to their diagnostic utility or help in the prediction of novel therapeutic targets. The applied framework is further able to enhance the understanding of complex psychiatric diseases, and may give novel insights into drug development and personalized medicine different approaches.

The the mechanism of action of standard drug treatments for psychiatric disorders remains fundamentally unknown, despite intensive investigation in academia and the of pharmaceutical industry. So far, little is known about the effects of psychotropic medications on brain metabolism in either humans or despite animals. In this study, we investigated the effects of a range of psychotropic drugs on rat brain metabolites. The drugs viability. investigated were haloperidol, clozapine, olanzapine, risperidone, aripiprazole (antipsychotics); valproate, carbamazapine (mood stabilizers) and phenytoin (antiepileptic drug). The relative concentrations of metabolites endogenous metabolites were determined using high-resolution proton nuclear magnetic resonance (1H NMR) spectroscopy. The results revealed that different classes of revealed psychotropic drugs modulated a range of metabolites, where each drug induced a distinct neurometabolic profile. Some common responses across several disorders drugs or within a class of drug were also observed. Antipsychotic drugs and mood stabilizers, with the exception of olanzapine,drug consistently increased N-acetylaspartate (NAA) levels in at least one brain area, suggesting a common therapeutic response on increased neuronal viability.drugs Most drugs also altered the levels of several metabolites associated with glucose metabolism, neurotransmission (including glutamate and aspartate) and inositols.fundamentally The heterogenic pharmacological response reflects the functional and physiological diversity of the therapeutic interventions, including side effects. Further study of action these metabolites in preclinical models should facilitate the development of novel drug treatments for psychiatric disorders with improved efficacy and with side effect profiles.

Schizophrenia with is one of the most severe psychiatric disorders affecting 1% of the world population. There is yet no empirical method of to validate the diagnosis of the disease. The identification of an underlying molecular alteration could lead to an improved disease psychiatric understanding and may yield an objective panel of biomarkers to aid in the diagnosis of this devastating disease. Presented is patients the largest reported liquid chromatography-mass spectrometry-based proteomic profiling study investigating serum samples taken from first-onset drug-naive patients compared with samples improved collected from healthy volunteers. The results of this large-scale study are presented along with enzyme-linked immunosorbent assay-based validation data.Molecular Psychiatry objective advance online publication, 23 June 2009; doi:10.1038/mp.2009.54.

Apolipoprotein with D (apoD) is a lipid binding protein expressed in the brain where its function is largely unknown. Based on changes in in lipid metabolism and deposition that occur in the human brain during postnatal development, we investigated changes in apoD expression its in the prefrontal cortex in 69 normal cases ranging in age from 40 days to 49 years utilizing gene microarray,into quantitative PCR and western blotting methods. In contrast to the high expression of apolipoprotein E (APOE), low-density lipoprotein receptor-related protein low-density 8 (LRP8) and 3-hydroxy-3-methyl-glutaryl-CoA reducatase (HMGCR)(genes that play a role in lipid-related pathways in brain development) early in life,role apoD expression was low in neonates and increased in expression throughout life resulting in six- to eight-fold higher levels at with the mRNA and protein levels in adults. Recent studies suggest that apoD has a novel antioxidant function in the brain binding and we found that the increased apoD expression throughout development and into adulthood was correlated with the expression of antioxidant six- genes superoxide dismutase 1 (SOD1) and glutathione peroxidase 3 (GPX3) as well as proteins that were modified by the lipid brain peroxidation end-product 4-hydroxynonenal. These studies reveal that apoD expression is increased throughout life in the human prefrontal cortex and that is this is correlated with genetic and biochemical markers of oxidative stress.

ABSTRACT:protein BACKGROUND: Many critical maturational processes take place in the human brain during postnatal development. In particular, the prefrontal cortex does to not reach maturation until late adolescence and this stage is associated with substantial white matter volume increases. Patients with schizophrenia prefrontal and other major psychiatric disorders tend to first present with overt symptoms during late adolescence/early adulthood and it has been genes proposed that this developmental stage represents a "window of vulnerability". METHODS: In this study we used whole genome microarrays to identify measure gene expression in post mortem prefrontal cortex tissue from human individuals ranging in age from to 49 years.which To identify genes specifically altered in the late adolescent period, we applied a template matching procedure. Genes were identified which involved showed a significant correlation to a template showing a peak of expression between ages 15 and 25. RESULTS: Approximately 2000 in genes displayed an expression pattern that was significantly correlated (positively or negatively) with the template. In the majority of cases,negatively) these genes in fact reached a plateau during adolescence with only subtle changes thereafter. These include a number of genes In previously associated with schizophrenia including the susceptibility gene neuregulin 1 (NRG1). Functional profiling revealed peak expression in late adolescence for maturational genes associated with energy metabolism and protein and lipid synthesis, together with decreases for genes involved in glutamate and neuropeptide adolescent signalling and neuronal development/plasticity. Strikingly, eight myelin-related genes previously found decreased in schizophrenia brain tissue showed a peak in their tissue expression levels in late adolescence, while the single myelin gene reported increased in patients with schizophrenia was decreased in late lipid adolescence. CONCLUSIONS: The observed changes imply that molecular mechanisms involved in adolescent brain development are disturbed in schizophrenia patients.